Verastem is a highly asymmetric oncology bet: newly commercial in rare ovarian cancer, potentially transformative in KRAS G12D tumors, but exposed to binary trial risk and dilution.
Overview
Verastem Oncology has transitioned into a commercial-stage biotech following FDA accelerated approval of AVMAPKI FAKZYNJA CO-PACK for recurrent KRAS-mutated LGSOC. Revenue currently comes solely from U.S. sales of this novel oral RAF/MEK clamp plus FAK inhibitor combination, distributed through Onco360. The drug addresses a rare ovarian cancer segment with poor chemotherapy responsiveness and limited alternatives. Management is pursuing Europe and Japan expansion while building a KRAS G12D pipeline through VS-7375, creating meaningful upside but heavy dependence on clinical, regulatory, and commercial execution.